Gossamer Bio, Inc.

Public companies file this within four business days when something important happens that investors should know about before the next quarterly report.

Gossamer Bio, Inc. filed this to release information to investors under Regulation FD — usually a press release, conference presentation, or other event the company considers important. Announces Extension of Early Tender Date for Exchange Offer and Consent Solicitation with Respect to Existing Convertible Notes San Diego, California. (NASDAQ: GOSS) (the “Company” or “Gossamer”), a biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonar…